Literature DB >> 12124422

Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.

L Iacovelli1, V Bruno, L Salvatore, D Melchiorri, R Gradini, A Caricasole, E Barletta, A De Blasi, F Nicoletti.   

Abstract

We used cultured cerebellar granule cells to examine whether native group-III metabotropic glutamate (mGlu) receptors are coupled to the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI-3-K) pathways. Cultured granule cells responded to the group-III mGlu receptor agonist, L-2-amino-4-phosphonobutanoate (l-AP4), with an increased phosphorylation and activity of MAPKs (ERK-1 and -2) and an increased phosphorylation of the PI-3-K target, protein kinase B (PKB/AKT). These effects were attenuated by the group-III antagonists, alpha-methyl-serine-O -phosphate (MSOP) and (R,S )-alpha-cyclopropyl-4-phosphonophenylglycine (CPPG), or by pretreatment of the cultures with pertussis toxin. l-AP4 also induced the nuclear translocation of beta-catenin, a downstream effector of the PI-3-K pathway. To assess the functional relevance of these mechanisms we examined the ability of l-AP4 to protect granule cells against apoptosis by trophic deprivation, induced by lowering extracellular K(+) from 25 to 10 mm. Neuroprotection by l-AP4 was attenuated by MSOP and abrogated by the compounds PD98059 and UO126, which inhibit the MAPK pathway, or by the compound LY294002, which inhibits the PI-3-K pathway. Taken together, these results show for the first time that native group-III mGlu receptors are coupled to MAPK and PI-3-K, and that activation of both pathways is necessary for neuroprotection mediated by this particular class of receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124422     DOI: 10.1046/j.1471-4159.2002.00929.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

1.  Group III metabotropic glutamate receptors as autoreceptors in the cerebellar cortex.

Authors:  Matthias Lorez; Urs Humbel; Marie-Claire Pflimlin; James N C Kew
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 2.  Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Authors:  Todd D Prickett; Yardena Samuels
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

3.  Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7.

Authors:  Zhenglin Gu; Wenhua Liu; Jing Wei; Zhen Yan
Journal:  J Biol Chem       Date:  2012-01-27       Impact factor: 5.157

4.  A new signalling pathway for parallel fibre presynaptic type 4 metabotropic glutamate receptors (mGluR4) in the rat cerebellar cortex.

Authors:  Karine Abitbol; Heather McLean; Thomas Bessiron; Hervé Daniel
Journal:  J Physiol       Date:  2012-05-08       Impact factor: 5.182

5.  Activation of Type 4 Metabotropic Glutamate Receptor Attenuates Oxidative Stress-Induced Death of Neural Stem Cells with Inhibition of JNK and p38 MAPK Signaling.

Authors:  Zhichao Zhang; Wen Ma; Li Wang; Hanshi Gong; Yumei Tian; Jianshui Zhang; Jianxin Liu; Haixia Lu; Xinlin Chen; Yong Liu
Journal:  Stem Cells Dev       Date:  2015-09-01       Impact factor: 3.272

Review 6.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

Review 7.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

8.  High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Authors:  Wu Yang; He Maolin; Zhao Jinmin; Wang Zhe
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-08       Impact factor: 4.553

Review 9.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

Review 10.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.